Literature DB >> 692294

Liver and thymus lipid composition in AKR mice with and without lymphomas.

S Kitada, L Mwasi, J F Mead, E F Hays.   

Abstract

Lipid composition of liver and thymus in controls, early stage lymphoma, and advanced stage lymphoma-bearing AKR mice was studied. There was a significant decrease in the liver total lipid content in mice with advanced lymphoma, whereas in the early stages, no quantitative change was seen. In livers of mice with advanced stage lymphoma, there was a significant decrease in the nonpolar fraction. The decrease was in triglyceride, whereas the cholesterol fractions were relatively increased though hig,ly variable. There was an increase in the polar lipid/nonpolar lipid ratio in the advanced lymphoma livers and a very large increase in the polar lipid/triglyceride ratio, indicating that the decrease in total lipid in these livers was largely in the triglyceride fraction. Similar changes were seen in the thymus, in which the lipid composition reflected the transformation from normal to malignant cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 692294     DOI: 10.1007/BF02533614

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  12 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Effect of neoplasia and fasting on phospholipid turnover rate in rat liver.

Authors:  G WEBER; A CANTERO
Journal:  Biochim Biophys Acta       Date:  1959-09

3.  Studies on plasma membranes. XXII. Fatty acid profiles of lipid classes in plasma membranes of rat and mouse livers and hepatomas.

Authors:  R P Van Hoeven; P Emmelot; J H Krol; E P Oomen-Meulemans
Journal:  Biochim Biophys Acta       Date:  1975-01-24

4.  Biochemical changes of the lipid in biopsied livers of patients with malignant neoplastic diseases.

Authors:  I Nakazawa; S Yamagata
Journal:  Tohoku J Exp Med       Date:  1971-02       Impact factor: 1.848

5.  Effect of antilymphocytic and antithymocytic sera on the development of mouse lymphoma.

Authors:  D L Vredevoe; E F Hays
Journal:  Cancer Res       Date:  1969-09       Impact factor: 12.701

6.  Hepatic lipids in tumor-bearing (glioma) mice.

Authors:  A A Stein; E Opalka; I Rosenblum
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

7.  Hepatoma, host liver, and normal rat liver phospholipids as affected by diet.

Authors:  R Wood
Journal:  Lipids       Date:  1975-12       Impact factor: 1.880

8.  Sequential hepatic triglycerides in tumor-bearing mice.

Authors:  A A Stein; E Opalka; D Serrone
Journal:  Cancer Res       Date:  1966-08       Impact factor: 12.701

9.  Further studies on lipid-chemical differences between cancerous and adenomatous polypous tissues in the human large intestine.

Authors:  I Nakazawa; S Yamagata; H Watanabe
Journal:  Tohoku J Exp Med       Date:  1976       Impact factor: 1.848

10.  Effect of essential fatty acid deficiency on the lipid composition of the Yoshida ascites hepatoma (AH 130) and of the liver and blood plasma from host and normal rats.

Authors:  S Ruggieri; A Fallani; D Tombaccini
Journal:  J Lipid Res       Date:  1976-09       Impact factor: 5.922

View more
  4 in total

1.  Lipid composition of Morris hepatoma 5123c, and of livers and blood plasma from host and normal rats.

Authors:  S Ruggieri; A Fallani
Journal:  Lipids       Date:  1979-09       Impact factor: 1.880

2.  Effect of hepatoma on host liver, heart and lung lipids as tumor growth progresses.

Authors:  R Wood; A Zoeller; M Matocha
Journal:  Lipids       Date:  1982-11       Impact factor: 1.880

3.  A lipid mobilizing factor in serum of tumor-bearing mice.

Authors:  S Kitada; E F Hays; J F Mead
Journal:  Lipids       Date:  1980-03       Impact factor: 1.880

4.  Changes in the activities of lipoprotein lipase and the lipogenic enzymes in tumor-bearing rats.

Authors:  S Lanza-Jacoby; E E Miller; F E Rosato
Journal:  Lipids       Date:  1982-12       Impact factor: 1.880

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.